Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up from $586.0 million a year earlier, but shifted from profit to a net loss of $92.1 million, or $(0.40) per diluted share, versus diluted EPS of $0.20 in Q1 2025.
Results were pressured by $33.5 million in non-recurring restructuring and related charges tied to a U.S. weight-loss offering shift and $17.6 million of fair value losses on liabilities plus $9.7 million on equity securities. The company still generated $89.4 million in operating cash flow and ended the quarter with $222.3 million in cash and $528.6 million in short-term investments.
Hims & Hers closed the $153.0 million YourBio acquisition, continued integrating prior Medici and Zava deals, and outlined a planned Eucalyptus purchase for up to $1.15 billion. It also carried $1.0 billion of 0% convertible notes due 2030 and recorded a $15.0 million accrual related to an FTC ROSCA investigation.
Hims & Hers Health, Inc. reported first quarter 2026 revenue of $608.1 million, up 4% from $586.0 million a year earlier, driven by nearly 2.6 million subscribers, an increase of 9%. Rest of world revenue rose sharply while U.S. revenue declined 8%.
Profitability deteriorated as gross margin fell to 65% from 73%. The company swung to a net loss of $92.1 million from net income of $49.5 million, and Adjusted EBITDA declined to $44.3 million from $91.1 million, with margin compressing to 7%.
Management highlighted a strategic pivot expanding branded GLP-1 offerings and recorded restructuring and legal settlement charges. Despite near-term margin pressure, the company generated $53.0 million in Free Cash Flow and raised full-year 2026 guidance to $2.8–$3.0 billion in revenue and $275–$350 million in Adjusted EBITDA, targeting a 10–12% margin.
Hims & Hers Health, Inc. is asking stockholders to vote at its June 11, 2026 virtual annual meeting on three items: electing nine directors, ratifying KPMG LLP as auditor for 2026, and approving executive pay on an advisory basis. The Board unanimously recommends voting “FOR” all proposals.
The proxy highlights strong 2025 performance, with revenue of $2.35 billion, up 59% year over year, and more than 2.5 million subscribers, up 13%. Net income was $128.4 million, compared with $126.0 million in 2024, while Adjusted EBITDA reached $318.0 million. Operating cash flow was $300.0 million and Free Cash Flow was $57.4 million.
The company is a NYSE “controlled company” because CEO Andrew Dudum, through Class A and high-vote Class V shares, holds over 50% of voting power and approximately 87.7% of total voting power. Despite this status, a majority of directors are independent, and all audit and compensation committee members are independent. The proxy also describes board committee structures, risk oversight, diversity metrics, and a pay program that is heavily equity-based and performance-linked, with executives earning about 94% of target 2025 bonuses based on revenue and Adjusted EBITDA results.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 9,463 shares of Class A Common Stock in an open-market transaction at $30.00 per share. After the sale, Boughton directly holds 299,368 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
Hims & Hers Health Chief Financial Officer Oluyemi Okupe exercised stock options and sold shares of Class A Common Stock. On April 20, 2026, he exercised options for 7,000 shares at $11.53 and 5,553 shares at $5.01, acquiring a total of 12,553 shares. The same day, he completed an open-market sale of 19,645 shares at an average price of $29.9626, under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, he held 262,954 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021. The filing notes the options exercised were fully vested, with some awards vesting monthly over four years beginning April 1, 2023.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported option exercises and share sales under a pre-arranged Rule 10b5-1 trading plan. On April 16–17, Okupe sold a total of 54,927 shares of Class A Common Stock in open-market transactions at average prices of $25.8964 and $27.8344. He also exercised stock options for 6,184 shares at an exercise price of $5.01 per share, converting derivative awards into common stock. Following these transactions, Okupe holds 270,046 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust, and retains stock options representing 129,403 shares expiring on February 23, 2032.
HIMS reported proposed sales of Class A common stock under Form 144. The filing lists proposed transfers tied to restricted stock vesting with amounts of 4,651 shares (12/15/2025) and 4,812 shares (03/15/2026). The excerpt also shows prior sales in the past three months: 4,651 shares sold on 02/27/2026 for $70,741.71 and 4,812 shares sold on 03/17/2026 for $118,808.28.
Hims & Hers Health, Inc. Chief Executive Officer Andrew Dudum reported a bona fide gift of a total of 845,866 shares of Class A Common Stock on April 9, 2026. The Form 4 shows two gift transactions of 422,933 shares each, recorded as non-derivative dispositions with no price paid.
After the gifts, Dudum holds 887,684 shares directly. He also has indirect holdings through several trusts, including 470,457 shares held by the Trustee of the Dudum Family Community Property Trust and additional blocks held in various Dudum family and GRAT trusts. These entries reflect estate and trust planning rather than open-market trading activity.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised stock options and sold the resulting shares. He exercised options for 3,975 shares of Class A Common Stock at an exercise price of $5.01 per share, then sold 3,975 shares at an average price of $19.977 per share.
The option exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 21, 2025. After these transactions, he holds 318,789 shares directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated September 1, 2021.